NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with anemia due to IPSS-R defined very low-, low-, or intermediate-risk MDS-RS who require RBC transfusions and who are refractory, intolerant or ineligible to prior erythropoiesis-stimulating agents (ESA) treatment
1 total trials
Filter these 1 trials by phase, country, sponsor and more.